TAK-625 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 297 | Alagille syndrome | 1 |
| 338 | Progressive familial intrahepatic cholestasis | 1 |
297. Alagille syndrome
Clinical trials : 45 / Drugs : 21 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05543174 (ClinicalTrials.gov) | January 16, 2023 | 14/9/2022 | A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome | Alagille Syndrome (ALGS) | Drug: TAK-625 | Takeda | NULL | Recruiting | 1 Month | N/A | All | 5 | Phase 3 | Japan |
338. Progressive familial intrahepatic cholestasis
Clinical trials : 60 / Drugs : 26 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05543187 (ClinicalTrials.gov) | January 10, 2023 | 14/9/2022 | A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) | An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis | Progressive Familial Intrahepatic Cholestasis (PFIC) | Drug: TAK-625 | Takeda | NULL | Recruiting | 1 Month | N/A | All | 9 | Phase 3 | Japan |